(Q28371388)

English

KRAS G12V

genetic variant

GLY12VAL
G12V
RS121913529

In more languages

Statements

missense mutation

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

human chromosome 12

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

25398284

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

25398284

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

biological variant of

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

positive therapeutic predictor for

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level D

CIViC 1-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/795

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

negative therapeutic predictor for

medical condition treated

statement disputed by

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

determination method

CIViC evidence level C

CIViC 2-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1715

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2268

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/136

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/6323

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/6323

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/3924

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2219

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/3824

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

negative prognostic predictor for

non-small-cell lung carcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/987

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases

Identifiers

CIViC variant ID

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_004985.4:c.35G>T

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

NP_004976.2:p.Gly12Val

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

NC_000012.11:g.25398284C>A

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

ENST00000256078.4:c.35G>T

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371388&oldid=2014799228"